Randomized, Double-Blind, Placebo-Controlled Phase IIB Trial of the Cyclooxygenase Inhibitor Ketorolac as an Oral Rinse in Oropharyngeal Leukoplakia

Clinical Cancer Research

Volumn 10, Issue 5, 2004, Pages 1565-1573

  Mulshine, James L ^a   Atkinson, Jane C ^b,g   Greer, Robert O ^c   Papadimitrakopoulou, Vassiliki A ^d   Van Waes, Carter ^e   Rudy, Susan ^e   Martin, Jack W ^d   Steinberg, Seth M ^a   Liewehr, David J ^a   Avis, Ingalill ^a   Linnoila, R Ilona ^a   Hewitt, Stephen ^a   Lippman, Scott M ^d   Frye, Robin ^a   Cavanaugh Jr , Paul F ^f  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF DENTAL MEDICINE   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f PROCTER AND GAMBLE COMPANY   (United States)

^g UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KETOROLAC; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTAGLANDIN SYNTHASE INHIBITOR;

APHTHOUS ULCER; ARTICLE; CAUCASIAN; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DYSPEPSIA; ENZYME INHIBITION; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HISTOPATHOLOGY; HUMAN; LEUKOPLAKIA; MALE; MOUTHWASH; NAUSEA; PATHOLOGICAL ANATOMY; PERIODONTAL DISEASE; PRIORITY JOURNAL; PUNCH BIOPSY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STOMATITIS; TASTE DISORDER; UPPER GASTROINTESTINAL TRACT; VOMITING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KETOROLAC; LEUKOPLAKIA, ORAL; MALE; MOUTHWASHES; OROPHARYNGEAL NEOPLASMS; PLACEBOS; SMOKING;

EID: 12144287878     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-1020-3     Document Type: Article

References (63)

1. Jemal, A., Thomas, A., Murray, T., Ghafoor, A., Ward, E., and Thun, M. J. Cancer Statistics, 2003. CA - Cancer J. Clin., 53: 5-26, 2003.
2. Day, T. A., Davis, B. K., Gillespie, M. B., Joe, J. K., Kibbey, M., Martin-Harris, B., Neville, B., Richardson, M. S., Rosenzweig, S., Sharma, A. K., Smith, M. M., Stewart, S., and Stuart, R. K. Oral cancer treatment. Curr. Treat. Options Oncol., 4: 27-41, 2003.
3. Neville, B. W., and Day, T. A. Oral cancer and precancerous lesions. CA - Cancer J Clin, 52: 195-215, 2002.
4. Hong, S. H., Ondrey, F. G., Avis, I. M., Chen, Z., Loukinova, E., Cavanaugh, P. F., Jr., Van Waes, C., and Mulshine, J. L. Cyclooxygenase regulates human oropharyngeal carcinomas via the proinflammatory cytokine IL-6: a general role for inflammation? FASEB J., 14: 1499-1507, 2000.
5. Renkonen, J., Wolff, H., and Paavonen, T. Expression of cyclooxygenase-2 in human tongue carcinoma and its precursor lesions. Virchows Arch., 440: 594-597, 2002.
6. Lin, D. T., Subbaramaiah, K., Shah, J. P., Dannenberg, A. J., and Boyle, J. O. Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer. Head Neck, 24: 792-799, 2002.
7. Dannenberg, A. J., Altorki, N. K., Boyle, J. O., Lin, D. T., and Subbaramaiah, K. Inhibition of cyclooxygenase-2: an approach to preventing cancer of the upper aerodigestive tract. Ann. N. Y. Acad. Sci., 952: 109-115, 2001.
8. Perkins, T. M., and Shklar, G. Delay in hamster buccal pouch carcinogenesis by aspirin and indomethacin. Oral Surg. Oral Med. Oral Pathol., 53: 170-178, 1982.
9. Cornwall, H., Odukoya, O., and Shklar, G. Oral mucosal tumor inhibition by ibuprofen. J. Oral Maxillofac. Surg., 41: 795-800, 1983.
10. Tanaka, T., Nishikawa, A., Mori, Y., Morishita, Y., and Mori, H. Inhibitory effects of non-steroidal anti-inflammatory drugs, piroxicam and indomethacin on 4-nitroquinoline 1-oxide-induced tongue carcinogenesis in male ACI/N rats. Cancer Lett., 48: 177-182, 1989.
11. Shiotani, H., Denda, A., Yamamoto, K., Kitayama, W., Endoh, T., Sasaki, Y., Tsutsumi, N., Sugimura, M., and Konishi, Y. Increased expression of cyclooxygenase-2 protein in 4-nitroquinoline-1-oxide-induced rat tongue carcinomas and chemopreventive efficacy of a specific inhibitor, nimesulide. Cancer Res., 61: 1451-1456, 2001.
12. Potter, M. Experimental plasmacytomagenesis in mice. Hematol. Oncol. Clin. N. Am., 11: 323-347, 1997.
13. Sudbo, J., and Reith, A. When is an oral leukoplakia premalignant? Oral Oncol, 38: 813-814; author reply 811-812, 2002.
14. Lippman, S. M., and Hong, W. K. Molecular markers of the risk of oral cancer. N. Engl. J. Med., 344: 1323-1326, 2001.
15. Lodi, G., Sardella, A., Bez, C., Demarosi, F., and Carrassi, A. Systematic review of randomized trials for the treatment of oral leukoplakia. J. Dent. Educ., 66: 896-902, 2002.
16. Karabulut, A., Reibel, J., Therkildsen, M. H., Praetorius, F., Nielsen, H. W., and Dabelsteen, E. Observer variability in the histologic assessment of oral premalignant lesions. J. Oral Pathol. Med., 24: 198-200, 1995.
17. Killen, J. P. The coxibs, selective inhibitors of cyclooxygenase-2. N. Engl. J. Med., 345: 1708; author reply 1709, 2001.
18. Labenz, J., Blum, A. L., Bolten, W. W., Dragosics, B., Rosch, W., Stolte, M., and Koelz, H. R. Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori-positive patients: a randomised, double blind, placebo controlled, clinical trial. Gut, 51: 329-335, 2002.
19. Laine, L., Bombardier, C., Hawkey, C. J., Davis, B., Shapiro, D., Brett, C., and Reicin, A. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology, 123: 1006-1012, 2002.
20. Laine, L., Connors, L. G., Reicin, A., Hawkey, C. J., Burgos-Vargas, R., Schnitzer, T. J., Yu, Q., and Bombardier, C. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology, 124: 288-292, 2003.
21. Llorente Melero, M. J., Tenias Burillo, J. M., and Zaragoza Marcet, A. Comparative incidence of upper gastrointestinal bleeding associated with individual non-steroidal anti-inflammatory drugs. Rev. Esp. Enferm. Dig., 94: 7-18, 2002.
22. Chan, F. K., Hung, L. C., Suen, B. Y., Wu, J. C., Lee, K. C., Leung, V. K., Hui, A. J., To, K. F., Leung, W. K., Wong, V. W., Chung, S. C., and Sung, J. J. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N. Engl. J. Med., 347: 2104-2110, 2002.
23. Chau, I., and Cunningham, D. Cyclooxygenase inhibition in cancer: a blind alley or a new therapeutic reality? N. Engl. J. Med., 346: 1085-1087, 2002.
24. Graham, D. Y. NSAIDs, Helicobacter pylori, and Pandora's Box. N. Engl. J. Med., 347: 2162-2164, 2002.
25. Kelm, G. R., Buchanan, W., Meredith, M. P., Offenbacher, S., Mankodi, S. M., Dobrozsi, D. J., Bapat, N. V., Collins, J. G., Wehmeyer, K. R., Eichhold, T. H., and Doyle, M. J. Evaluation of ketorolac concentrations in plasma and gingival crevicular fluid following topical treatment with oral rinses and dentifrices. J. Pharm. Sci., 85: 842-847, 1996.
26. Cavanaugh, P. F., Jr., Meredith, M. P., Buchanan, W., Doyle, M. J., Reddy, M. S., and Jeffcoat, M. K. Coordinate production of PGE2 and IL-1 β in the gingival crevicular fluid of adults with periodontitis: its relationship to alveolar bone loss and disruption by twice daily treatment with ketorolac tromethamine oral rinse. J. Periodontal Res., 33: 75-82, 1998.
27. Jeffcoat, M. K., Reddy, M. S., Haigh, S., Buchanan, W., Doyle, M. J., Meredith, M. P., Nelson, S. L., Goodale, M. B., and Wehmeyer, K. R. A comparison of topical ketorolac, systemic flurbiprofen, and placebo for the inhibition of bone loss in adult periodontitis. J. Periodontol., 66: 329-338, 1995.
28. Hong, W. K., Endicott, J., Itri, L. M., Doos, W., Batsakis, J. G., Bell, R., Fofonoff, S., Byers, R., Atkinson, E. N., Vaughan, C., et al. 13-Cis-retinoic acid in the treatment of oral leukoplakia. N. Engl. J. Med., 315: 1501-1505, 1986.
29. Simon, R. Optimal two-stage designs for Phase II clinical trials. Control Clin. Trials, 10: 1-10, 1989.
30. Sankaranarayanan, R., Mathew, B., Varghese, C., Sudhakaran, P. R., Menon, V., Jayadeep, A., Nair, M. K., Mathews, C., Mahalingam, T. R., Balaram, P., and Nair, P. P. Chemoprevention of oral leukoplakia with vitamin A and β-carotene: an assessment. Oral Oncol., 33: 231-236, 1997.
31. Agresti, A. Categorical Data Analysis, pp. 79-137. New York: John Wiley and Son, Inc., 1990.
32. Zelen, M. The analysis of several 2 × 2 contingency tables. Biometrika, 58: 129-137, 1971.
33. Schreinemachers, D. M., and Everson, R. B. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology, 5: 138-146, 1994.
34. Bosetti, C., Talamini, R., Franceschi, S., Negri, E., Garavello, W., and La Vecchia, C. Aspirin use and cancers of the upper aerodigestive tract. Br. J. Cancer, 88: 672-674, 2003.
35. Ballaz, S., and Mulshine, J. L. The potential contribution of chronic inflammation to lung carcinogenesis. Clin. Lung Cancer, 5: 46-62, 2003.
36. Brater, D. C., Harris, C., Redfern, J. S., and Gertz, B. J. Renal effects of COX-2 selective inhibitors. Am. J. Nephrol. 21: 1-15, 2001.
37. Tsujii, M., Kawano, S., Tsuji, S., Sawaoka, H., Hori, M., and DuBois, R. N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell, 93: 705-716, 1998.
38. Gupta, R. A., Tejada, L. V., Tong, B. J., Das, S. K., Morrow, J. D., Dey, S. K., and DuBois, R. N. Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res., 63: 906-911, 2003.
39. Offenbacher, S., Heasman, P. A., and Collins, J. G. Modulation of host PGE2 secretion as a determinant of periodontal disease expression. J. Periodontol., 64: 432-444, 1993.
40. Chvetzoff, G., and Tannock, I. F. Placebo effects in oncology. J. Natl. Cancer Inst. (Bethesda), 95: 19-29, 2003.
41. Paik, J., Lee, J. Y., and Hwang, D. Signaling pathways for TNFα-induced COX-2 expression: mediation through MAP kinases and NF-κB, and inhibition by certain nonsteroidal anti-inflammatory drugs. Adv. Exp. Med. Biol., 507: 503-508, 2002.
42. Maihofner, C., Charalambous, M. P., Bhambra, U., Lightfoot, T., Geisslinger, G., and Gooderham, N. J. Expression of cyclooxygenase-2 parallels expression of interleukin-1β, interleukin-6 and NF-κB in human colorectal cancer. Carcinogenesis (Lond.), 24: 665-671, 2003.
43. Van Dyke, T. E., and Serhan, C. N. Resolution of inflammation: a new paradigm for the pathogenesis of periodontal diseases. J. Dent. Res., 82: 82-90, 2003.
44. Campisi, G., and Margiotta, V. Oral mucosal lesions and risk habits among men in an Italian study population. J. Oral Pathol. Med., 30: 22-28, 2001.
45. Fokkema, S. J., Loos, B. G., and Van, D. V. U. Monocyte-derived RANTES is intrinsically elevated in periodontal disease while MCP-1 levels are related to inflammation and are inversely correlated with IL-12 levels. Clin. Exp. Immunol., 131: 477-483, 2003.
46. Delima, A. J., Karatzas, S., Amar, S., and Graves, D. T. Inflammation and tissue loss caused by periodontal pathogens is reduced by interleukin-1 antagonists. J. Infect. Dis., 186: 511-516, 2002.
47. Tozum, T. F., Berker, E., Ersoy, F., Tezcan, I., and Sanal, O. The relationship between periodontal status and peripheral levels of neutrophils in two consanguineous siblings with severe congenital neutropenia: case reports. Quintessence Int., 34: 221-226, 2003.
48. Chapple, I. L. Reactive oxygen species and antioxidants in inflammatory diseases. J. Clin. Periodontol., 24: 287-296, 1997.
49. Dodd, M. J., Larson, P. J., Dibble, S. L., Miaskowski, C., Greenspan, D., MacPhail, L., Hauck, W. W., Paul, S. M., Ignoffo, R., and Shiba, G. Randomized clinical trial of chlorhexidine versus placebo for prevention of oral mucositis in patients receiving chemotherapy. Oncol. Nurs. Forum, 23: 921-927, 1996.
50. Meiller, T. F., Kutcher, M. J., Overholser, C. D., Niehaus, C., DePaola, L. G., and Siegel, M. A. Effect of an antimicrobial mouthrinse on recurrent aphthous ulcerations. Oral Surg. Oral Med. Oral Pathol., 72: 425-429, 1991.
51. Banerjee, A. G., Gopalakrishnan, V. K., Bhattacharya, I., and Vishwanatha, J. K. Deregulated cyclooxygenase-2 expression in oral premalignant tissues. Mol. Cancer Ther, 1: 1265-1271, 2002.
52. Hasturk, S., Kemp, B., Kalapurakal, S. K., Kurie, J. M., Hong, W. K., and Lee, J. S. Expression of cyclooxygenase-1 and cyclooxygenase-2 in bronchial epithelium and non-small cell lung carcinoma. Cancer (Phila.), 94: 1023-1031, 2002.
53. Hong, S. H., Avis, I., Vos, M. D., Martinez, A., Treston, A. M., and Mulshine, J. L. Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors. Cancer Res., 59: 2223-2228, 1999.
54. Hida, T., Leyton, J., Makheja, A. N., Ben-Av, P., Hla, T., Martinez, A., Mulshine, J., Malkani, S., Chung, P., and Moody, T. W. Non-small cell lung cancer cycloxygenase activity and proliferation are inhibited by non-steroidal anti-inflammatory drugs. Anticancer Res., 18: 775-782, 1998.
55. O'Shaughnessy, J. A., Kelloff, G. J., Gordon, G. B., Dannenberg, A. J., Hong, W. K., Fabian, C. J., Sigman, C. C., Bertagnolli, M. M., Stratton, S. P., Lam, S., Nelson, W. G., Meyskens, F. L., Alberts, D. S., Follen, M., Rustgi, A. K., Papadimitrakopoulou, V., Scardino, P. T., Gazdar, A. F., Wattenberg, L. W., Sporn, M. B., Sakr, W. A., Lippman, S. M., and Von Hoff, D. D. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin. Cancer Res., 8: 314-346, 2002.
56. Mao, L., El-Naggar, A. K., Papadimitrakopoulou, V., Shin, D. M., Shin, H. C., Fan, Y., Zhou, X., Clayman, G., Lee, J. J., Lee, J. S., Hittelman, W. N., Lippman, S. M., and Hong, W. K. Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. J. Natl. Cancer Inst. (Bethesda), 90: 1545-1551, 1998.
57. Jarvis, B., and Figgitt, D. P. Topical 3% diclofenac in 2.5% hyaluronic acid gel: a review of its use in patients with actinic keratoses. Am. J. Clin. Dermatol., 4: 203-213, 2003.
58. Gebauer, K., Brown, P., and Varigos, G. Topical diclofenac in hyaluronan gel for the treatment of solar keratoses. Australas. J. Dermatol., 44: 40-43, 2003.
59. Peters, D. C., and Foster, R. H. Diclofenac/hyaluronic acid. Drugs Aging, 14: 313-319; discussion 320-311, 1999.
60. Moore, A. R., and Willoughby, D. A. Hyaluronan as a drug delivery system for diclofenac: a hypothesis for mode of action. Int. J. Tissue React., 17: 153-156, 1995.
61. Burkhart, C. N., and Burkhart, C. G. Reassessment of topical diclofenac/hyaluronan gel for actinic keratoses. Int. J. Dermatol., 41: 371-372, 2002.
62. Wolf, J. E., Jr., Taylor, J. R., Tschen, E., and Kang, S. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int. J. Dermatol., 40: 709-713, 2001.
63. Mulshine, J. L., De Luca, L. M., and Dedrick, R. L. Regional delivery of retinoids: a new approach to early lung cancer intervention, pp. 273-284. Basel, Switzerland: Birkhauser, 1998.